- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
Patent holdings for IPC class A61K 31/7125
Total number of patents in this class: 2024
10-year publication summary
|
74
|
113
|
116
|
119
|
140
|
134
|
184
|
184
|
161
|
96
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ionis Pharmaceuticals, Inc. | 930 |
138 |
| Alnylam Pharmaceuticals, Inc. | 1169 |
51 |
| Wave Life Sciences Ltd. | 208 |
39 |
| Sarepta Therapeutics, Inc. | 391 |
38 |
| The Board of Regents of the University of Texas System | 2267 |
29 |
| Hoffmann-La Roche Inc. | 3686 |
26 |
| Nippon Shinyaku Co., Ltd. | 321 |
26 |
| Geron Corporation | 159 |
25 |
| ProQR Therapeutics II B.V. | 122 |
25 |
| Empirico Inc. | 99 |
24 |
| University of Massachusetts | 2295 |
22 |
| Avidity Biosciences, Inc. | 194 |
20 |
| The Regents of the University of California | 20534 |
19 |
| Arrowhead Pharmaceuticals, Inc. | 336 |
19 |
| Korro Bio, Inc. | 77 |
19 |
| F. Hoffmann-La Roche AG | 7835 |
18 |
| Regulus Therapeutics Inc. | 72 |
18 |
| Daiichi Sankyo Company, Limited | 1887 |
17 |
| Biogen MA Inc. | 926 |
16 |
| Antisense Therapeutics Ltd. | 27 |
15 |
| Other owners | 1420 |